Clinical Trial Update: Lutetium-177-PSMA-617 in Low Volume Metastatic Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update for Lutetium-177-PSMA-617 in low-volume metastatic prostate cancer completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Lutetium-177 PSMA-617 (lutetium Lu-177 PSMA-617)

Snippet

Sponsor: Radboud University Medical Center | Conditions: Prostate Neoplasm | Phase 1, Phase 2 | Status: COMPLETED